RADIANT: Regulatory Science Empowering Innovation in Transformative Medical Software and AI.
Lead Participant:
UNIVERSITY OF WESTMINSTER
Abstract
The UK is a global pioneer in the medical software and artificial intelligence (AI) products sector, worth $188Bn globally by 2030\. The UK is already progressing evidence-based change in pro-innovation regulatory science in this area. Given its strategic importance and rapid technological innovation, there is increasing need for a supportive regulatory environment that encourages innovation while ensuring safety, inclusivity, robustness and efficacy. The lack of these conditions impinges on the ability of UK businesses to excel, lowers the quality of care that AI technology progress can deliver, and reduces the global competitiveness of the UK.
Barriers to commercialisation identified through our 'Evidence Generator' are: (i) opaque and disparate legislation; (ii) complex interplay with regulation in adjacent areas; (iii) friction to data flows; (iv) mismatch between technology development and evaluation methods; (v) over-emphasis on regulatory compliance, and not enough on payer needs and sustainability; (vi) regulatory uncertainty.
RADIANT will provide the expertise, networks, and skills to help solve these problems and identify improvements for the entire ecosystem. RADIANT will be an inclusive, vibrant, interdisciplinary network of medical software and AI businesses, researchers, legal and regulatory experts, policy-makers, clinicians, citizens/patients, payers, and commissioners, with opportunities to collaborate across health-related sectors (e.g. food, environment, finance) and adjacent regulation (e.g. data protection, intellectual property, financial incentives).
The RADIANT team has outstanding expertise in medical software and AI innovation for healthcare, and its regulation and adoption: two lead universities (Westminster, Brunel), two growth companies (science impact accelerator Helix Data Innovation, social impact venture builder Zinc.vc), and three further academic partners (Imperial College London, UCL, King's College London).
Through a knowledge-to-action approach, RADIANT will deliver a collaborative interdisciplinary programme of discovery and knowledge exchange to analyse barriers and opportunities, and will co-produce a cross-stakeholder strategy for practical solutions. By August 2024, we will have engaged with ~5,000 medical software and AI innovators, experts and regulatory stakeholders; begun a public conversation about fit-for-purpose regulation to support innovation and adoption; raised awareness and increased network capacity; have further developed our ideas for solutions; and identified priorities for next steps.
RADIANT will have tangible impact on medical software and AI innovators, and ultimately on health, the economy and society. RADIANT will deliver pro-innovation policies and conditions right across the product lifecycle, enabling the UK to remain a global leader, and supporting better health, quality of life and prosperity.
Barriers to commercialisation identified through our 'Evidence Generator' are: (i) opaque and disparate legislation; (ii) complex interplay with regulation in adjacent areas; (iii) friction to data flows; (iv) mismatch between technology development and evaluation methods; (v) over-emphasis on regulatory compliance, and not enough on payer needs and sustainability; (vi) regulatory uncertainty.
RADIANT will provide the expertise, networks, and skills to help solve these problems and identify improvements for the entire ecosystem. RADIANT will be an inclusive, vibrant, interdisciplinary network of medical software and AI businesses, researchers, legal and regulatory experts, policy-makers, clinicians, citizens/patients, payers, and commissioners, with opportunities to collaborate across health-related sectors (e.g. food, environment, finance) and adjacent regulation (e.g. data protection, intellectual property, financial incentives).
The RADIANT team has outstanding expertise in medical software and AI innovation for healthcare, and its regulation and adoption: two lead universities (Westminster, Brunel), two growth companies (science impact accelerator Helix Data Innovation, social impact venture builder Zinc.vc), and three further academic partners (Imperial College London, UCL, King's College London).
Through a knowledge-to-action approach, RADIANT will deliver a collaborative interdisciplinary programme of discovery and knowledge exchange to analyse barriers and opportunities, and will co-produce a cross-stakeholder strategy for practical solutions. By August 2024, we will have engaged with ~5,000 medical software and AI innovators, experts and regulatory stakeholders; begun a public conversation about fit-for-purpose regulation to support innovation and adoption; raised awareness and increased network capacity; have further developed our ideas for solutions; and identified priorities for next steps.
RADIANT will have tangible impact on medical software and AI innovators, and ultimately on health, the economy and society. RADIANT will deliver pro-innovation policies and conditions right across the product lifecycle, enabling the UK to remain a global leader, and supporting better health, quality of life and prosperity.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
UNIVERSITY OF WESTMINSTER | £11,165 | £ 11,165 |
  | ||
Participant |
||
HELIX DATA INNOVATION LTD | £20,000 | £ 20,000 |
BRUNEL UNIVERSITY LONDON | £8,767 | £ 8,767 |
ZINC VENTURES LIMITED | £10,000 | £ 10,000 |
UNIVERSITY COLLEGE LONDON | ||
IMPERIAL COLLEGE LONDON | ||
KING'S COLLEGE LONDON |
People |
ORCID iD |
Alexander Bolotov (Project Manager) |